|
|
To amend section 3719.41 of the Revised Code to add | 1 |
synthetic cannabinoids commonly known as K2 or | 2 |
Spice to the list of Schedule I controlled | 3 |
substances. | 4 |
Section 1. That section 3719.41 of the Revised Code be | 5 |
amended to read as follows: | 6 |
Sec. 3719.41. Controlled substance schedules I, II, III, IV, | 7 |
and V are hereby established, which schedules include the | 8 |
following, subject to amendment pursuant to section 3719.43 or | 9 |
3719.44 of the Revised Code. | 10 |
11 | |
(A) Narcotics-opiates | 12 |
Any of the following opiates, including their isomers, | 13 |
esters, ethers, salts, and salts of isomers, esters, and ethers, | 14 |
unless specifically excepted under federal drug abuse control | 15 |
laws, whenever the existence of these isomers, esters, ethers, and | 16 |
salts is possible within the specific chemical designation: | 17 |
(1) Acetyl-alpha-methylfentanyl | 18 |
(N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); | 19 |
(2) Acetylmethadol; | 20 |
(3) Allylprodine; | 21 |
(4) Alphacetylmethadol (except levo-alphacetylmethadol, also | 22 |
known as levo-alpha-acetylmethadol, levomethadyl acetate, or | 23 |
LAAM); | 24 |
(5) Alphameprodine; | 25 |
(6) Alphamethadol; | 26 |
(7) Alpha-methylfentanyl | 27 |
(N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; | 28 |
1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); | 29 |
(8) Alpha-methylthiofentanyl | 30 |
(N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- | 31 |
phenylpropanamide); | 32 |
(9) Benzethidine; | 33 |
(10) Betacetylmethadol; | 34 |
(11) Beta-hydroxyfentanyl | 35 |
(N-[1-(2-hydroxy-2-phenethyl-4-piperidinyl]-N- phenylpropanamide); | 36 |
(12) Beta-hydroxy-3-methylfentanyl (other name: | 37 |
N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N- | 38 |
phenylpropanamide); | 39 |
(13) Betameprodine; | 40 |
(14) Betamethadol; | 41 |
(15) Betaprodine; | 42 |
(16) Clonitazene; | 43 |
(17) Dextromoramide; | 44 |
(18) Diampromide; | 45 |
(19) Diethylthiambutene; | 46 |
(20) Difenoxin; | 47 |
(21) Dimenoxadol; | 48 |
(22) Dimepheptanol; | 49 |
(23) Dimethylthiambutene; | 50 |
(24) Dioxaphetyl butyrate; | 51 |
(25) Dipipanone; | 52 |
(26) Ethylmethylthiambutene; | 53 |
(27) Etonitazene; | 54 |
(28) Etoxeridine; | 55 |
(29) Furethidine; | 56 |
(30) Hydroxypethidine; | 57 |
(31) Ketobemidone; | 58 |
(32) Levomoramide; | 59 |
(33) Levophenacylmorphan; | 60 |
(34) 3-methylfentanyl | 61 |
(N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N- phenylpropanamide); | 62 |
(35) 3-methylthiofentanyl | 63 |
(N-[3-methyl-1-[2-(thienyl)ethyl]-4-piperidinyl]-N- | 64 |
phenylpropanamide); | 65 |
(36) Morpheridine; | 66 |
(37) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); | 67 |
(38) Noracymethadol; | 68 |
(39) Norlevorphanol; | 69 |
(40) Normethadone; | 70 |
(41) Norpipanone; | 71 |
(42) Para-fluorofentanyl | 72 |
(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide; | 73 |
(43) PEPAP (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine; | 74 |
(44) Phenadoxone; | 75 |
(45) Phenampromide; | 76 |
(46) Phenomorphan; | 77 |
(47) Phenoperidine; | 78 |
(48) Piritramide; | 79 |
(49) Proheptazine; | 80 |
(50) Properidine; | 81 |
(51) Propiram; | 82 |
(52) Racemoramide; | 83 |
(53) Thiofentanyl | 84 |
(N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide; | 85 |
(54) Tilidine; | 86 |
(55) Trimeperidine. | 87 |
(B) Narcotics-opium derivatives | 88 |
Any of the following opium derivatives, including their | 89 |
salts, isomers, and salts of isomers, unless specifically excepted | 90 |
under federal drug abuse control laws, whenever the existence of | 91 |
these salts, isomers, and salts of isomers is possible within the | 92 |
specific chemical designation: | 93 |
(1) Acetorphine; | 94 |
(2) Acetyldihydrocodeine; | 95 |
(3) Benzylmorphine; | 96 |
(4) Codeine methylbromide; | 97 |
(5) Codeine-n-oxide; | 98 |
(6) Cyprenorphine; | 99 |
(7) Desomorphine; | 100 |
(8) Dihydromorphine; | 101 |
(9) Drotebanol; | 102 |
(10) Etorphine (except hydrochloride salt); | 103 |
(11) Heroin; | 104 |
(12) Hydromorphinol; | 105 |
(13) Methyldesorphine; | 106 |
(14) Methyldihydromorphine; | 107 |
(15) Morphine methylbromide; | 108 |
(16) Morphine methylsulfonate; | 109 |
(17) Morphine-n-oxide; | 110 |
(18) Myrophine; | 111 |
(19) Nicocodeine; | 112 |
(20) Nicomorphine; | 113 |
(21) Normorphine; | 114 |
(22) Pholcodine; | 115 |
(23) Thebacon. | 116 |
(C) Hallucinogens | 117 |
Any material, compound, mixture, or preparation that contains | 118 |
any quantity of the following hallucinogenic substances, including | 119 |
their salts, isomers, and salts of isomers, unless specifically | 120 |
excepted under federal drug abuse control laws, whenever the | 121 |
existence of these salts, isomers, and salts of isomers is | 122 |
possible within the specific chemical designation. For the | 123 |
purposes of this division only, "isomer" includes the optical | 124 |
isomers, position isomers, and geometric isomers. | 125 |
(1) Alpha-ethyltryptamine (some trade or other names: | 126 |
etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; | 127 |
3-(2-aminobutyl) indole; alpha-ET; and AET); | 128 |
(2) 4-bromo-2,5-dimethoxyamphetamine (some trade or other | 129 |
names: 4-bromo-2,5-dimethoxy-alpha-methyphenethylamine; | 130 |
4-bromo-2,5-DMA); | 131 |
(3) 4-bromo-2,5-dimethoxyphenethylamine (some trade or other | 132 |
names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; | 133 |
alpha-desmethyl DOB; 2C-B, Nexus); | 134 |
(4) 2,5-dimethoxyamphetamine (some trade or other names: | 135 |
2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); | 136 |
(5) 2,5-dimethoxy-4-ethylamphetamine (some trade or other | 137 |
names: DOET); | 138 |
(6) 4-methoxyamphetamine (some trade or other names: | 139 |
4-methoxy-alpha-methylphenethylamine; paramethoxyamphetamine; | 140 |
PMA); | 141 |
(7) 5-methoxy-3,4-methylenedioxy-amphetamine; | 142 |
(8) 4-methyl-2,5-dimethoxy-amphetamine (some trade or other | 143 |
names: 4-methyl-2,5-dimethoxy-alpha-methylphenethylamine; "DOM" | 144 |
and "STP"); | 145 |
(9) 3,4-methylenedioxy amphetamine; | 146 |
(10) 3,4-methylenedioxymethamphetamine (MDMA); | 147 |
(11) 3,4-methylenedioxy-N-ethylamphetamine (also known as | 148 |
N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl | 149 |
MDA, MDE, MDEA); | 150 |
(12) N-hydroxy-3,4-methylenedioxyamphetamine (also known as | 151 |
N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine and | 152 |
N-hydroxy MDA); | 153 |
(13) 3,4,5-trimethoxy amphetamine; | 154 |
(14) Bufotenine (some trade or other names: | 155 |
3-(beta-dimethylaminoethyl)-5-hydroxyindole; | 156 |
3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; | 157 |
5-hydroxy-N, N-dimethyltryptamine; mappine); | 158 |
(15) Diethyltryptamine (some trade or other names: N, | 159 |
N-diethyltryptamine; DET); | 160 |
(16) Dimethyltryptamine (some trade or other names: DMT); | 161 |
(17) Ibogaine (some trade or other names: | 162 |
7-ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano- | 163 |
5H-pyrido[1',2':1,2] azepino [5, 4-b] indole; tabernanthe iboga); | 164 |
(18) Lysergic acid diethylamide; | 165 |
(19) Marihuana; | 166 |
(20) Mescaline; | 167 |
(21) Parahexyl (some trade or other names: 3-hexyl-1- | 168 |
hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; | 169 |
synhexyl); | 170 |
(22) Peyote (meaning all parts of the plant presently | 171 |
classified botanically as "Lophophora williamsii Lemaire," whether | 172 |
growing or not, the seeds of that plant, any extract from any part | 173 |
of that plant, and every compound, manufacture, salts, derivative, | 174 |
mixture, or preparation of that plant, its seeds, or its | 175 |
extracts); | 176 |
(23) N-ethyl-3-piperidyl benzilate; | 177 |
(24) N-methyl-3-piperidyl benzilate; | 178 |
(25) Psilocybin; | 179 |
(26) Psilocyn; | 180 |
(27) Tetrahydrocannabinols (synthetic equivalents of the | 181 |
substances contained in the plant, or in the resinous extractives | 182 |
of Cannabis, sp. and/or synthetic substances, derivatives, and | 183 |
their isomers with similar chemical structure and pharmacological | 184 |
activity such as the following: delta-1-cis or trans | 185 |
tetrahydrocannabinol, and their optical isomers; delta-6-cis or | 186 |
trans tetrahydrocannabinol, and their optical isomers; | 187 |
delta-3,4-cis or trans tetrahydrocannabinol, and its optical | 188 |
isomers. (Since nomenclature of these substances is not | 189 |
internationally standardized, compounds of these structures, | 190 |
regardless of numerical designation of atomic positions, are | 191 |
covered.)); | 192 |
(28) Ethylamine analog of phencyclidine (some trade or other | 193 |
names: N-ethyl-1-phenylcyclohexylamine; | 194 |
(1-phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; | 195 |
cyclohexamine; PCE); | 196 |
(29) Pyrrolidine analog of phencyclidine (some trade or other | 197 |
names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP); | 198 |
(30) Thiophene analog of phencyclidine (some trade or other | 199 |
names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine; 2-thienyl analog | 200 |
of phencyclidine; TPCP; TCP); | 201 |
(31) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine; | 202 |
(32) Hashish; | 203 |
(33) Salvia divinorum; | 204 |
(34) Salvinorin A; | 205 |
(35) 1-pentyl-3-(1-naphthoyl) indole (some trade or other | 206 |
names: JWH-018); | 207 |
(36) 1-butyl-3-(1-naphthoyl) indole (some trade or other | 208 |
names: JWH-073). | 209 |
(D) Depressants | 210 |
Any material, compound, mixture, or preparation that contains | 211 |
any quantity of the following substances having a depressant | 212 |
effect on the central nervous system, including their salts, | 213 |
isomers, and salts of isomers, unless specifically excepted under | 214 |
federal drug abuse control laws, whenever the existence of these | 215 |
salts, isomers, and salts of isomers is possible within the | 216 |
specific chemical designation: | 217 |
(1) Mecloqualone; | 218 |
(2) Methaqualone. | 219 |
(E) Stimulants | 220 |
Unless specifically excepted or unless listed in another | 221 |
schedule, any material, compound, mixture, or preparation that | 222 |
contains any quantity of the following substances having a | 223 |
stimulant effect on the central nervous system, including their | 224 |
salts, isomers, and salts of isomers: | 225 |
(1) Aminorex (some other names: aminoxaphen; | 226 |
2-amino-5-phenyl-2-oxazoline; or | 227 |
4,5-dihydro-5-phenyl-2-oxazolamine); | 228 |
(2) Cathinone (some trade or other names: | 229 |
2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, | 230 |
2-aminopropiophenone, and norephedrone); | 231 |
(3) Fenethylline; | 232 |
(4) Methcathinone (some other names: | 233 |
2-(methylamino)-propiophenone; alpha-(methylamino)propiophenone; | 234 |
2-methylamino)-1-phenylpropan-1-one; | 235 |
alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; | 236 |
N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and | 237 |
UR1432, its salts, optical isomers, and salts of optical isomers; | 238 |
(5) (+/-)cis-4-methylaminorex | 239 |
((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); | 240 |
(6) N-ethylamphetamine; | 241 |
(7) N,N-dimethylamphetamine (also known as | 242 |
N,N-alpha-trimethyl-benzeneethanamine; | 243 |
N,N-alpha-trimethylphenethylamine). | 244 |
245 | |
(A) Narcotics-opium and opium derivatives | 246 |
Unless specifically excepted under federal drug abuse control | 247 |
laws or unless listed in another schedule, any of the following | 248 |
substances whether produced directly or indirectly by extraction | 249 |
from substances of vegetable origin, independently by means of | 250 |
chemical synthesis, or by a combination of extraction and chemical | 251 |
synthesis: | 252 |
(1) Opium and opiate, and any salt, compound, derivative, or | 253 |
preparation of opium or opiate, excluding apomorphine, | 254 |
thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, | 255 |
naloxone, and naltrexone, and their respective salts, but | 256 |
including the following: | 257 |
(a) Raw opium; | 258 |
(b) Opium extracts; | 259 |
(c) Opium fluid extracts; | 260 |
(d) Powdered opium; | 261 |
(e) Granulated opium; | 262 |
(f) Tincture of opium; | 263 |
(g) Codeine; | 264 |
(h) Ethylmorphine; | 265 |
(i) Etorphine hydrochloride; | 266 |
(j) Hydrocodone; | 267 |
(k) Hydromorphone; | 268 |
(l) Metopon; | 269 |
(m) Morphine; | 270 |
(n) Oxycodone; | 271 |
(o) Oxymorphone; | 272 |
(p) Thebaine. | 273 |
(2) Any salt, compound, derivative, or preparation thereof | 274 |
that is chemically equivalent to or identical with any of the | 275 |
substances referred to in division (A)(1) of this schedule, except | 276 |
that these substances shall not include the isoquinoline alkaloids | 277 |
of opium; | 278 |
(3) Opium poppy and poppy straw; | 279 |
(4) Coca leaves and any salt, compound, derivative, or | 280 |
preparation of coca leaves (including cocaine and ecgonine, their | 281 |
salts, isomers, and derivatives, and salts of those isomers and | 282 |
derivatives), and any salt, compound, derivative, or preparation | 283 |
thereof that is chemically equivalent to or identical with any of | 284 |
these substances, except that the substances shall not include | 285 |
decocainized coca leaves or extraction of coca leaves, which | 286 |
extractions do not contain cocaine or ecgonine; | 287 |
(5) Concentrate of poppy straw (the crude extract of poppy | 288 |
straw in either liquid, solid, or powder form that contains the | 289 |
phenanthrene alkaloids of the opium poppy). | 290 |
(B) Narcotics-opiates | 291 |
Unless specifically excepted under federal drug abuse control | 292 |
laws or unless listed in another schedule, any of the following | 293 |
opiates, including their isomers, esters, ethers, salts, and salts | 294 |
of isomers, esters, and ethers, whenever the existence of these | 295 |
isomers, esters, ethers, and salts is possible within the specific | 296 |
chemical designation, but excluding dextrorphan and | 297 |
levopropoxyphene: | 298 |
(1) Alfentanil; | 299 |
(2) Alphaprodine; | 300 |
(3) Anileridine; | 301 |
(4) Bezitramide; | 302 |
(5) Bulk dextropropoxyphene (non-dosage forms); | 303 |
(6) Carfentanil; | 304 |
(7) Dihydrocodeine; | 305 |
(8) Diphenoxylate; | 306 |
(9) Fentanyl; | 307 |
(10) Isomethadone; | 308 |
(11) Levo-alphacetylmethadol (some other names: | 309 |
levo-alpha-acetylmethadol; levomethadyl acetate; LAAM); | 310 |
(12) Levomethorphan; | 311 |
(13) Levorphanol; | 312 |
(14) Metazocine; | 313 |
(15) Methadone; | 314 |
(16) Methadone-intermediate, | 315 |
4-cyano-2-dimethylamino-4,4-diphenyl butane; | 316 |
(17) Moramide-intermediate, | 317 |
2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic acid; | 318 |
(18) Pethidine (meperidine); | 319 |
(19) Pethidine-intermediate-A, | 320 |
4-cyano-1-methyl-4-phenylpiperidine; | 321 |
(20) Pethidine-intermediate-B, | 322 |
ethyl-4-phenylpiperidine-4-carboxylate; | 323 |
(21) Pethidine-intermediate-C, | 324 |
1-methyl-4-phenylpiperidine-4-carboxylic acid; | 325 |
(22) Phenazocine; | 326 |
(23) Piminodine; | 327 |
(24) Racemethorphan; | 328 |
(25) Racemorphan; | 329 |
(26) Remifentanil; | 330 |
(27) Sufentanil. | 331 |
(C) Stimulants | 332 |
Unless specifically excepted under federal drug abuse control | 333 |
laws or unless listed in another schedule, any material, compound, | 334 |
mixture, or preparation that contains any quantity of the | 335 |
following substances having a stimulant effect on the central | 336 |
nervous system: | 337 |
(1) Amphetamine, its salts, its optical isomers, and salts of | 338 |
its optical isomers; | 339 |
(2) Methamphetamine, its salts, its isomers, and salts of its | 340 |
isomers; | 341 |
(3) Methylphenidate; | 342 |
(4) Phenmetrazine and its salts. | 343 |
(D) Depressants | 344 |
Unless specifically excepted under federal drug abuse control | 345 |
laws or unless listed in another schedule, any material, compound, | 346 |
mixture, or preparation that contains any quantity of the | 347 |
following substances having a depressant effect on the central | 348 |
nervous system, including their salts, isomers, and salts of | 349 |
isomers, whenever the existence of these salts, isomers, and salts | 350 |
of isomers is possible within the specific chemical designation: | 351 |
(1) Amobarbital; | 352 |
(2) Gamma-hydroxy-butyrate; | 353 |
(3) Glutethimide; | 354 |
(4) Pentobarbital; | 355 |
(5) Phencyclidine (some trade or other names: | 356 |
1-(1-phenylcyclohexyl)piperidine; PCP); | 357 |
(6) Secobarbital; | 358 |
(7) 1-aminophenylcyclohexane and all N-mono-substituted | 359 |
and/or all N-N-disubstituted analogs including, but not limited | 360 |
to, the following: | 361 |
(a) 1-phenylcyclohexylamine; | 362 |
(b) (1-phenylcyclohexyl) methylamine; | 363 |
(c) (1-phenylcyclohexyl) dimethylamine; | 364 |
(d) (1-phenylcyclohexyl) methylethylamine; | 365 |
(e) (1-phenylcyclohexyl) isopropylamine; | 366 |
(f) 1-(1-phenylcyclohexyl) morpholine. | 367 |
(E) Hallucinogenic substances | 368 |
(1) Nabilone (another name for nabilone: | 369 |
(+)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1- | 370 |
hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one). | 371 |
(F) Immediate precursors | 372 |
Unless specifically excepted under federal drug abuse control | 373 |
laws or unless listed in another schedule, any material, compound, | 374 |
mixture, or preparation that contains any quantity of the | 375 |
following substances: | 376 |
(1) Immediate precursor to amphetamine and methamphetamine: | 377 |
(a) Phenylacetone (some trade or other names: | 378 |
phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl | 379 |
ketone); | 380 |
(2) Immediate precursors to phencyclidine (PCP): | 381 |
(a) 1-phenylcyclohexylamine; | 382 |
(b) 1-piperidinocyclohexanecarbonitrile (PCC). | 383 |
384 | |
(A) Stimulants | 385 |
Unless specifically excepted under federal drug abuse control | 386 |
laws or unless listed in another schedule, any material, compound, | 387 |
mixture, or preparation that contains any quantity of the | 388 |
following substances having a stimulant effect on the central | 389 |
nervous system, including their salts, their optical isomers, | 390 |
position isomers, or geometric isomers, and salts of these | 391 |
isomers, whenever the existence of these salts, isomers, and salts | 392 |
of isomers is possible within the specific chemical designation: | 393 |
(1) All stimulant compounds, mixtures, and preparations | 394 |
included in schedule III pursuant to the federal drug abuse | 395 |
control laws and regulations adopted under those laws; | 396 |
(2) Benzphetamine; | 397 |
(3) Chlorphentermine; | 398 |
(4) Clortermine; | 399 |
(5) Phendimetrazine. | 400 |
(B) Depressants | 401 |
Unless specifically excepted under federal drug abuse control | 402 |
laws or unless listed in another schedule, any material, compound, | 403 |
mixture, or preparation that contains any quantity of the | 404 |
following substances having a depressant effect on the central | 405 |
nervous system: | 406 |
(1) Any compound, mixture, or preparation containing | 407 |
amobarbital, secobarbital, pentobarbital, or any salt of any of | 408 |
these drugs, and one or more other active medicinal ingredients | 409 |
that are not listed in any schedule; | 410 |
(2) Any suppository dosage form containing amobarbital, | 411 |
secobarbital, pentobarbital, or any salt of any of these drugs and | 412 |
approved by the food and drug administration for marketing only as | 413 |
a suppository; | 414 |
(3) Any substance that contains any quantity of a derivative | 415 |
of barbituric acid or any salt of a derivative of barbituric acid; | 416 |
(4) Chlorhexadol; | 417 |
(5) Ketamine, its salts, isomers, and salts of isomers (some | 418 |
other names for ketamine: | 419 |
(+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone); | 420 |
(6) Lysergic acid; | 421 |
(7) Lysergic acid amide; | 422 |
(8) Methyprylon; | 423 |
(9) Sulfondiethylmethane; | 424 |
(10) Sulfonethylmethane; | 425 |
(11) Sulfonmethane; | 426 |
(12) Tiletamine, zolazepam, or any salt of tiletamine or | 427 |
zolazepam (some trade or other names for a tiletamine-zolazepam | 428 |
combination product: Telazol); (some trade or other names for | 429 |
tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone); (some | 430 |
trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8- | 431 |
dihydro-1,3,8-trimethylpyrazolo-[3, 4-e][1,4]-diazepin-7(1H)-one; | 432 |
flupyrazapon). | 433 |
(C) Narcotic antidotes | 434 |
(1) Nalorphine. | 435 |
(D) Narcotics-narcotic preparations | 436 |
Unless specifically excepted under federal drug abuse control | 437 |
laws or unless listed in another schedule, any material, compound, | 438 |
mixture, or preparation that contains any of the following | 439 |
narcotic drugs, or their salts calculated as the free anhydrous | 440 |
base or alkaloid, in limited quantities as set forth below: | 441 |
(1) Not more than 1.8 grams of codeine per 100 milliliters or | 442 |
not more than 90 milligrams per dosage unit, with an equal or | 443 |
greater quantity of an isoquinoline alkaloid of opium; | 444 |
(2) Not more than 1.8 grams of codeine per 100 milliliters or | 445 |
not more than 90 milligrams per dosage unit, with one or more | 446 |
active, nonnarcotic ingredients in recognized therapeutic amounts; | 447 |
(3) Not more than 300 milligrams of dihydrocodeinone per 100 | 448 |
milliliters or not more than 15 milligrams per dosage unit, with a | 449 |
fourfold or greater quantity of an isoquinoline alkaloid of opium; | 450 |
(4) Not more than 300 milligrams of dihydrocodeinone per 100 | 451 |
milliliters or not more than 15 milligrams per dosage unit, with | 452 |
one or more active, nonnarcotic ingredients in recognized | 453 |
therapeutic amounts; | 454 |
(5) Not more than 1.8 grams of dihydrocodeine per 100 | 455 |
milliliters or not more than 90 milligrams per dosage unit, with | 456 |
one or more active, nonnarcotic ingredients in recognized | 457 |
therapeutic amounts; | 458 |
(6) Not more than 300 milligrams of ethylmorphine per 100 | 459 |
milliliters or not more than 15 milligrams per dosage unit, with | 460 |
one or more active, nonnarcotic ingredients in recognized | 461 |
therapeutic amounts; | 462 |
(7) Not more than 500 milligrams of opium per 100 milliliters | 463 |
or per 100 grams or not more than 25 milligrams per dosage unit, | 464 |
with one or more active, nonnarcotic ingredients in recognized | 465 |
therapeutic amounts; | 466 |
(8) Not more than 50 milligrams of morphine per 100 | 467 |
milliliters or per 100 grams, with one or more active, nonnarcotic | 468 |
ingredients in recognized therapeutic amounts. | 469 |
(E) Anabolic steroids | 470 |
Unless specifically excepted under federal drug abuse control | 471 |
laws or unless listed in another schedule, any material, compound, | 472 |
mixture, or preparation that contains any quantity of the | 473 |
following substances, including their salts, esters, isomers, and | 474 |
salts of esters and isomers, whenever the existence of these | 475 |
salts, esters, and isomers is possible within the specific | 476 |
chemical designation: | 477 |
(1) Anabolic steroids. Except as otherwise provided in | 478 |
division (E)(1) of schedule III, "anabolic steroids" means any | 479 |
drug or hormonal substance that is chemically and | 480 |
pharmacologically related to testosterone (other than estrogens, | 481 |
progestins, and corticosteroids) and that promotes muscle growth. | 482 |
"Anabolic steroids" does not include an anabolic steroid that is | 483 |
expressly intended for administration through implants to cattle | 484 |
or other nonhuman species and that has been approved by the United | 485 |
States secretary of health and human services for that | 486 |
administration, unless a person prescribes, dispenses, or | 487 |
distributes this type of anabolic steroid for human use. "Anabolic | 488 |
steroid" includes, but is not limited to, the following: | 489 |
(a) Boldenone; | 490 |
(b) Chlorotestosterone (4-chlortestosterone); | 491 |
(c) Clostebol; | 492 |
(d) Dehydrochlormethyltestosterone; | 493 |
(e) Dihydrotestosterone (4-dihydrotestosterone); | 494 |
(f) Drostanolone; | 495 |
(g) Ethylestrenol; | 496 |
(h) Fluoxymesterone; | 497 |
(i) Formebulone (formebolone); | 498 |
(j) Mesterolone; | 499 |
(k) Methandienone; | 500 |
(l) Methandranone; | 501 |
(m) Methandriol; | 502 |
(n) Methandrostenolone; | 503 |
(o) Methenolone; | 504 |
(p) Methyltestosterone; | 505 |
(q) Mibolerone; | 506 |
(r) Nandrolone; | 507 |
(s) Norethandrolone; | 508 |
(t) Oxandrolone; | 509 |
(u) Oxymesterone; | 510 |
(v) Oxymetholone; | 511 |
(w) Stanolone; | 512 |
(x) Stanozolol; | 513 |
(y) Testolactone; | 514 |
(z) Testosterone; | 515 |
(aa) Trenbolone; | 516 |
(bb) Any salt, ester, isomer, or salt of an ester or isomer | 517 |
of a drug or hormonal substance described or listed in division | 518 |
(E)(1) of schedule III if the salt, ester, or isomer promotes | 519 |
muscle growth. | 520 |
(F) Hallucinogenic substances | 521 |
(1) Dronabinol (synthetic) in sesame oil and encapsulated in | 522 |
a soft gelatin capsule in a United States food and drug | 523 |
administration approved drug product (some other names for | 524 |
dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- | 525 |
6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or | 526 |
(-)-delta-9-(trans)-tetrahydrocannabinol). | 527 |
528 | |
(A) Narcotic drugs | 529 |
Unless specifically excepted by federal drug abuse control | 530 |
laws or unless listed in another schedule, any material, compound, | 531 |
mixture, or preparation that contains any of the following | 532 |
narcotic drugs, or their salts calculated as the free anhydrous | 533 |
base or alkaloid, in limited quantities as set forth below: | 534 |
(1) Not more than one milligram of difenoxin and not less | 535 |
than 25 micrograms of atropine sulfate per dosage unit; | 536 |
(2) Dextropropoxyphene | 537 |
(alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- | 538 |
propionoxybutane)[final dosage forms]. | 539 |
(B) Depressants | 540 |
Unless specifically excepted under federal drug abuse control | 541 |
laws or unless listed in another schedule, any material, compound, | 542 |
mixture, or preparation that contains any quantity of the | 543 |
following substances, including their salts, isomers, and salts of | 544 |
isomers, whenever the existence of these salts, isomers, and salts | 545 |
of isomers is possible within the specific chemical designation: | 546 |
(1) Alprazolam; | 547 |
(2) Barbital; | 548 |
(3) Bromazepam; | 549 |
(4) Camazepam; | 550 |
(5) Chloral betaine; | 551 |
(6) Chloral hydrate; | 552 |
(7) Chlordiazepoxide; | 553 |
(8) Clobazam; | 554 |
(9) Clonazepam; | 555 |
(10) Clorazepate; | 556 |
(11) Clotiazepam; | 557 |
(12) Cloxazolam; | 558 |
(13) Delorazepam; | 559 |
(14) Diazepam; | 560 |
(15) Estazolam; | 561 |
(16) Ethchlorvynol; | 562 |
(17) Ethinamate; | 563 |
(18) Ethyl loflazepate; | 564 |
(19) Fludiazepam; | 565 |
(20) Flunitrazepam; | 566 |
(21) Flurazepam; | 567 |
(22) Halazepam; | 568 |
(23) Haloxazolam; | 569 |
(24) Ketazolam; | 570 |
(25) Loprazolam; | 571 |
(26) Lorazepam; | 572 |
(27) Lormetazepam; | 573 |
(28) Mebutamate; | 574 |
(29) Medazepam; | 575 |
(30) Meprobamate; | 576 |
(31) Methohexital; | 577 |
(32) Methylphenobarbital (mephobarbital); | 578 |
(33) Midazolam; | 579 |
(34) Nimetazepam; | 580 |
(35) Nitrazepam; | 581 |
(36) Nordiazepam; | 582 |
(37) Oxazepam; | 583 |
(38) Oxazolam; | 584 |
(39) Paraldehyde; | 585 |
(40) Petrichloral; | 586 |
(41) Phenobarbital; | 587 |
(42) Pinazepam; | 588 |
(43) Prazepam; | 589 |
(44) Quazepam; | 590 |
(45) Temazepam; | 591 |
(46) Tetrazepam; | 592 |
(47) Triazolam; | 593 |
(48) Zaleplon; | 594 |
(49) Zolpidem. | 595 |
(C) Fenfluramine | 596 |
Any material, compound, mixture, or preparation that contains | 597 |
any quantity of the following substances, including their salts, | 598 |
their optical isomers, position isomers, or geometric isomers, and | 599 |
salts of these isomers, whenever the existence of these salts, | 600 |
isomers, and salts of isomers is possible within the specific | 601 |
chemical designation: | 602 |
(1) Fenfluramine. | 603 |
(D) Stimulants | 604 |
Unless specifically excepted under federal drug abuse control | 605 |
laws or unless listed in another schedule, any material, compound, | 606 |
mixture, or preparation that contains any quantity of the | 607 |
following substances having a stimulant effect on the central | 608 |
nervous system, including their salts, their optical isomers, | 609 |
position isomers, or geometric isomers, and salts of these | 610 |
isomers, whenever the existence of these salts, isomers, and salts | 611 |
of isomers is possible within the specific chemical designation: | 612 |
(1) Cathine ((+)-norpseudoephedrine); | 613 |
(2) Diethylpropion; | 614 |
(3) Fencamfamin; | 615 |
(4) Fenproporex; | 616 |
(5) Mazindol; | 617 |
(6) Mefenorex; | 618 |
(7) Modafinil; | 619 |
(8) Pemoline (including organometallic complexes and chelates | 620 |
thereof); | 621 |
(9) Phentermine; | 622 |
(10) Pipradrol; | 623 |
(11) Sibutramine; | 624 |
(12) SPA [(-)-1-dimethylamino-1,2-diphenylethane]. | 625 |
(E) Other substances | 626 |
Unless specifically excepted under federal drug abuse control | 627 |
laws or unless listed in another schedule, any material, compound, | 628 |
mixture, or preparation that contains any quantity of the | 629 |
following substances, including their salts: | 630 |
(1) Pentazocine; | 631 |
(2) Butorphanol (including its optical isomers). | 632 |
633 | |
(A) Narcotic drugs | 634 |
Unless specifically excepted under federal drug abuse control | 635 |
laws or unless listed in another schedule, any material, compound, | 636 |
mixture, or preparation that contains any of the following | 637 |
narcotic drugs, and their salts, as set forth below: | 638 |
(1) Buprenorphine. | 639 |
(B) Narcotics-narcotic preparations | 640 |
Narcotic drugs containing non-narcotic active medicinal | 641 |
ingredients. Any compound, mixture, or preparation that contains | 642 |
any of the following narcotic drugs, or their salts calculated as | 643 |
the free anhydrous base or alkaloid, in limited quantities as set | 644 |
forth below, and that includes one or more nonnarcotic active | 645 |
medicinal ingredients in sufficient proportion to confer upon the | 646 |
compound, mixture, or preparation valuable medicinal qualities | 647 |
other than those possessed by narcotic drugs alone: | 648 |
(1) Not more than 200 milligrams of codeine per 100 | 649 |
milliliters or per 100 grams; | 650 |
(2) Not more than 100 milligrams of dihydrocodeine per 100 | 651 |
milliliters or per 100 grams; | 652 |
(3) Not more than 100 milligrams of ethylmorphine per 100 | 653 |
milliliters or per 100 grams; | 654 |
(4) Not more than 2.5 milligrams of diphenoxylate and not | 655 |
less than 25 micrograms of atropine sulfate per dosage unit; | 656 |
(5) Not more than 100 milligrams of opium per 100 milliliters | 657 |
or per 100 grams; | 658 |
(6) Not more than 0.5 milligram of difenoxin and not less | 659 |
than 25 micrograms of atropine sulfate per dosage unit. | 660 |
(C) Stimulants | 661 |
Unless specifically exempted or excluded under federal drug | 662 |
abuse control laws or unless listed in another schedule, any | 663 |
material, compound, mixture, or preparation that contains any | 664 |
quantity of the following substances having a stimulant effect on | 665 |
the central nervous system, including their salts, isomers, and | 666 |
salts of isomers: | 667 |
(1) Ephedrine, except as provided in division (K) of section | 668 |
3719.44 of the Revised Code; | 669 |
(2) Pyrovalerone. | 670 |
Section 2. That existing section 3719.41 of the Revised Code | 671 |
is hereby repealed. | 672 |